PAF launches CINV CareLine to assist patients with cancer, CINV

NewsGuard 100/100 Score

Nausea and Vomiting Present Obstacles to Patients' Life-Saving Chemotherapy Maintenance; CareLine Program Provides Direct Assistance to Patients Experiencing Side Effects of Chemotherapy, Seeking Access to Anti-Nausea Care

Patient Advocate Foundation (PAF) – a national non-profit organization that seeks to safeguard patients through effective mediation assuring access to care, maintenance of employment and preservation of their financial stability relative to their diagnosis of life threatening or debilitating diseases – is pleased to announce that it has launched a new program, the CINV (Chemotherapy-Induced Nausea and Vomiting) CareLine. The CareLine is a toll-free hotline, 877-614-9242, designed to provide individualized case management assistance to patients diagnosed with cancer and experiencing chemotherapy-induced nausea and vomiting.

"Patient Advocate Foundation is committed to improving the quality of life of patients facing medical hardships through our professional case management and CareLine services. We are excited to launch the CINV CareLine, which will allow us to assist a larger number of cancer patients across the nation that are seeking education about advancements in anti-nausea medications and access to this important care," said Nancy Davenport-Ennis, Founder and CEO of PAF.  "A cancer diagnosis can be the most overwhelming experience a person may ever face in his or her lifetime. Coupled with the side effects of treatment, the journey can be worrisome and uncomfortable, so we are pleased to provide this additional assistance to help improve patients' quality of life."

Approximately eight out of every ten people treated with chemotherapy experience nausea and vomiting, two frequent side effects that tend to cause substantial worry for patients. Termed Chemotherapy-Induced Nausea and Vomiting, or CINV, the condition can negatively affect a patient's quality of life, making it hard to function normally from day to day. Because of their often debilitating nausea and vomiting side effects, many patients consider stopping chemotherapy treatment completely.

Along with improvements in chemotherapy, much advancement has been made in the medications that are available today to control nausea and vomiting. When these medicines are used correctly, nausea and vomiting can be prevented in the majority of people. In fact, many nurses and doctors have adopted a zero tolerance approach to chemotherapy-induced nausea and vomiting through the use of such medications.

The CINV CareLine is staffed by a team of clinical case managers with both nursing and social work background who provide individualized service to patients, their caregivers and providers who are seeking information and/or assistance with the following:

  • Navigation and assistance through the reimbursement system, including initial interpretation of the patient's benefit language
  • Direct appeals assistance
  • Educational resources, including disease specific literature, managed care information and financial resource information
  • Referrals and linkage to appropriate educational resources
  • Clinical trials education and clinical trials screening
  • Connection  to all known local, state and/or national resources for financial assistance
  • Case management services to uninsured patients, ensuring access to care and enrollment into Medicaid and/or charity care programs, when appropriate

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Gut microbiome study challenges established cancer biomarkers, identifies new bacterial links to colorectal cancer